Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$12.65
-2.7%
$11.42
$3.98
$13.40
$1.93B1.922.03 million shs628,351 shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.33
-4.0%
$1.39
$0.85
$2.72
$400.99M2.179.78 million shs3.18 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$27.49
-3.9%
$33.54
$24.28
$55.33
$1.66B2.361.19 million shs609,360 shs
10x Genomics stock logo
TXG
10x Genomics
$14.00
-2.1%
$12.59
$6.78
$24.76
$1.74B2.033.42 million shs1.02 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
0.00%-0.31%+20.93%+45.58%+167.49%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
0.00%+5.34%-10.39%+49.71%-11.54%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%+1.67%-20.56%+1.17%-34.52%
10x Genomics stock logo
TXG
10x Genomics
0.00%+7.04%+1.35%+75.03%-39.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.564 of 5 stars
1.41.00.04.22.61.70.6
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.608 of 5 stars
3.23.00.00.03.20.01.3
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.1409 of 5 stars
3.42.00.04.44.00.80.6
10x Genomics stock logo
TXG
10x Genomics
3.8763 of 5 stars
2.22.00.04.83.82.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.88
Moderate Buy$12.38-2.18% Downside
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.43
Hold$1.9043.40% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.73
Moderate Buy$49.4079.73% Upside
10x Genomics stock logo
TXG
10x Genomics
2.38
Hold$13.54-3.27% Downside

Current Analyst Ratings Breakdown

Latest TXG, ADPT, PACB, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
10x Genomics stock logo
TXG
10x Genomics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
8/12/2025
10x Genomics stock logo
TXG
10x Genomics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$18.00 ➝ $17.00
8/11/2025
10x Genomics stock logo
TXG
10x Genomics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$16.00
8/11/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$1.25 ➝ $1.50
8/8/2025
10x Genomics stock logo
TXG
10x Genomics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$12.00 ➝ $13.00
8/8/2025
10x Genomics stock logo
TXG
10x Genomics
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetHold ➝ Hold$14.00
8/8/2025
10x Genomics stock logo
TXG
10x Genomics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$13.00 ➝ $15.00
8/6/2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$10.00 ➝ $14.00
8/6/2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
8/6/2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$13.00 ➝ $15.00
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$205.22M9.39N/AN/A$1.37 per share9.23
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$154.01M2.58N/AN/A$1.85 per share0.72
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M5.30N/AN/A$8.07 per share3.41
10x Genomics stock logo
TXG
10x Genomics
$610.78M2.85N/AN/A$5.81 per share2.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$159.49M-$0.82N/AN/AN/A-59.07%-60.93%-23.03%11/6/2025 (Estimated)
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$309.85M-$2.29N/AN/AN/A-336.40%-66.75%-16.90%11/6/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$1.45N/AN/AN/A-23.51%-29.03%-21.77%N/A
10x Genomics stock logo
TXG
10x Genomics
-$182.63M-$0.70N/AN/AN/A-13.13%-12.88%-10.03%10/27/2025 (Estimated)

Latest TXG, ADPT, PACB, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.18-$0.13+$0.05-$0.14$36.35 million$39.77 million
8/7/2025Q2 2025
10x Genomics stock logo
TXG
10x Genomics
-$0.35$0.28+$0.63$0.28$139.36 million$172.91 million
8/5/2025Q2 2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.24-$0.17+$0.07-$0.17$49.40 million$49.94 million
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54-$0.47+$0.07$0.33$95.52 million$96.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
10x Genomics stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/A
2.84
2.75
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
10.51
6.92
6.02
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
3.90
3.60
10x Genomics stock logo
TXG
10x Genomics
N/A
5.84
5.23
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
790152.27 million142.53 millionOptionable
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
730300.37 million293.16 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99060.36 million58.54 millionOptionable
10x Genomics stock logo
TXG
10x Genomics
1,240124.49 million112.00 millionOptionable

Recent News About These Companies

10x Genomics $TXG Stock Holdings Lessened by SVB Wealth LLC
3 Reasons TXG is Risky and 1 Stock to Buy Instead
2 Growth Stocks Cathie Wood Is Buying Non-Stop
Leerink Partners Remains a Hold on 10x Genomics (TXG)
J.P. Morgan Remains a Hold on 10x Genomics (TXG)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$12.65 -0.35 (-2.68%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Pacific Biosciences of California stock logo

Pacific Biosciences of California NASDAQ:PACB

$1.32 -0.06 (-3.99%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$27.48 -1.11 (-3.86%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

10x Genomics stock logo

10x Genomics NASDAQ:TXG

$14.00 -0.30 (-2.10%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.